Daëron Marc, Lesourne Renaud
Unité d'Allergologie Moléculaire et Cellulaire, Département d'Immunologie, Institut Pasteur, Paris, France.
Adv Immunol. 2006;89:39-86. doi: 10.1016/S0065-2776(05)89002-9.
Cell activation results from the transient displacement of an active balance between positive and negative signaling. This displacement depends in part on the engagement of cell surface receptors by extracellular ligands. Among these are receptors for the Fc portion of immunoglobulins (FcRs). FcRs are widely expressed by cells of hematopoietic origin. When binding antibodies, FcRs provide these cells with immunoreceptors capable of triggering numerous biological responses in response to a specific antigen. FcR-dependent cell activation is regulated by negative signals which are generated together with positive signals within signalosomes that form upon FcR engagement. Many molecules involved in positive signaling, including the FcRbeta subunit, the src kinase lyn, the cytosolic adapter Grb2, and the transmembrane adapters LAT and NTAL, are indeed also involved in negative signaling. A major player in negative regulation of FcR signaling is the inositol 5-phosphatase SHIP1. Several layers of negative regulation operate sequentially as FcRs are engaged by extracellular ligands with an increasing valency. A background protein tyrosine phosphatase-dependent negative regulation maintains cells in a "resting" state. SHIP1-dependent negative regulation can be detected as soon as high-affinity FcRs are occupied by antibodies in the absence of antigen. It increases when activating FcRs are engaged by multivalent ligands and, further, when FcR aggregation increases, accounting for the bell-shaped dose-response curve observed in excess of ligand. Finally, F-actin skeleton-associated high-molecular weight SHIP1, recruited to phosphorylated ITIMs, concentrates in signaling complexes when activating FcRs are coengaged with inhibitory FcRs by immune complexes. Based on these data, activating and inhibitory FcRs could be used for new therapeutic approaches to immune disorders.
细胞活化源于正负信号之间活性平衡的短暂改变。这种改变部分取决于细胞外配体与细胞表面受体的结合。其中包括免疫球蛋白Fc段的受体(FcRs)。FcRs在造血来源的细胞中广泛表达。当结合抗体时,FcRs为这些细胞提供免疫受体,使其能够针对特定抗原触发多种生物学反应。FcR依赖的细胞活化由负信号调节,这些负信号与FcR结合时形成的信号小体中的正信号一起产生。许多参与正信号传导的分子,包括FcRβ亚基、src激酶lyn、胞质衔接蛋白Grb2以及跨膜衔接蛋白LAT和NTAL,实际上也参与负信号传导。FcR信号负调节的一个主要参与者是肌醇5-磷酸酶SHIP1。随着FcRs与细胞外配体以增加的价态结合,几层负调节依次起作用。背景蛋白酪氨酸磷酸酶依赖性负调节使细胞维持在“静止”状态。一旦高亲和力FcRs在没有抗原的情况下被抗体占据,就可以检测到SHIP1依赖性负调节。当活化FcRs与多价配体结合时,以及进一步当FcR聚集增加时,负调节增强,这解释了在过量配体时观察到的钟形剂量反应曲线。最后,当活化FcRs与抑制性FcRs被免疫复合物共同结合时,募集到磷酸化免疫受体酪氨酸抑制基序的F-肌动蛋白骨架相关高分子量SHIP1集中在信号复合物中。基于这些数据,活化性和抑制性FcRs可用于免疫疾病的新治疗方法。